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Abstract 
Based on the structure of 4’,8-dihydroxyisoflavon-7-yl α-D-arabinofuranoside 
(namely A-76202, 1), a Rhodococcus metabolite showing potent inhibitory activities 
against the α-glucosidases of rat liver microsome (IC50 = 0.46 ng/mL), 26 analogs 
each with minor variations at the sugar moiety, the isoflavone A, and B rings, 
respectively, are readily synthesized. Notably, a new and efficient method is 
developed for the divergent synthesis of the B-ring congeners of the isoflavone 
glycosides using Suzuki-Miyaura coupling as the final step. Modifications at the 
sugar moiety and the isoflavone A ring significantly diminish the activity, while 
variations on the B ring are largely tolerated for retaining the potent α-glucosidase 
inhibitory activity. 
 
Introduction
The generation of glycoproteins involves the cotranslational transference of 
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the tetradeca-oligosaccharide Glc3Man9GlcNAc2 from the dolichyl diphosphate to the 
N-asparagine of the nascent protein, by the action of the oligosaccharyl-transferase in 
the lumen of the reticulum endoplasmatic membrane.[1] Then the processing enzymes, 
α-glucosidase I and II, cleave the Glc(1→2)Glc and Glc(1→3)Glc linkages in this 
N-linked oligosaccharide respectively, to liberate the three terminal glucose 
residues.[2] This immature glycoprotein is further processed by the concomitant action 
of glycosidases and transferases to give specific glycoconjugates, which play 
fundamental roles in the biological processes, such as the immune response, 
intercellular recognition, cellular differentiation, the stability and solubility of proteins, 
and in pathological processes, such as inflammation and cancer.[3] Tremendous efforts 
have been given to the development of glucosidase inhibitors which are of potentially 
usefulness for the treatment of diabetes,[4] obesity,[5] glycosphingolipid lysosomal 
storage disease,[6] HIV infections,[7] and tumors.[8] The potent inhibitors with IC50 at 
nM level are largely structural mimics of the transition state of the hydrolyses of the 
glucosidic linkage.[9] In this regard, 4’,8-dihydroxyisoflavon-7-yl 
α-D-arabinofuranoside (1) is an exception which shows potent inhibitory activity 
(against the α-glucosidases of rat liver mcrosome) with an IC50 of 0.46 ng/mL.[10] This 
isoflavone glycoside, named A-76202, was isolated by Takatsuki et al. in 1996 from 
Rhodococcus sp. SANK 61694. Shiozaki et al. have synthesized this compound along 
with several hexopyranoside analogs (2), and evaluated their α-glucosidase inhibitory 
activities.[11] However, these hexose analogs were found inactive. We have developed 
a general approach to the synthesis of flavone 7-O-glycosides, such as A-76202 (1).[12] 
Here we report the synthesis of a series of the analogs of 1, each with minor variations 
at the sugar moiety, the isoflavone A, and B rings, respectively, and the evaluation of 
their α-glucosidase inhibitory activities. 
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Figure 1. A-76202 (1) and the hexose analogues (2) synthesized by Shiozaki et al. 
 
Results and Discussion 
Synthesis 
Adopting modification of our previous method for the synthesis of flavone 
7-O-glycosides,[12] the desired 4’,8-dihydroxyisoflavon-7-yl pentosides (9a-d) and the 
natural product 1 as well were readily prepared via glycosylation of the ready 
available 4’,8-di-O-hexanoyl isoflavone derivative 8[12] with the corresponding 
peracetyl pentosyl trichloroacetimidates 3-7[13-17] under the promotion of BF3·OEt2 
and subsequent removal of the acyl groups with K2CO3 in a mixed solvent of 
MeOH/THF/H2O (Scheme 1). The yields (over two steps) are only moderate 
(26%-76%); partial migration of the 8-O-hexanoyl group onto the neighboring 7-OH 
under the glycosylation conditions was observed. 
1 α-D-arabinofuranoside (58%)
9a α-L-arabinofuranoside (26%)
9b β-D-ribofuranoside (60%)
9c β-D-xylofuranoside (46%)
9d β-D-xylopyranoside (76%)
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 Scheme 1. Synthesis of the 4’,8-dihydroxyisoflavon-7-yl pentosides 1 and 9a-d. 
 
To synthesize the A and B ring congeners of A-76202 (1), a divergent 
approach by using Suzuki-Miyaura coupling[18] of a 3-bromo-4H-chromen-7-yl 
α-D-arabinofuranoside (i.e., 15 and 21) with a panel of the commercially available 
aryl boronic acids as the final step was envisioned. The required chromen-3-bromides 
15 and 21 were prepared as shown in Schemes 2 and 3. 
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Scheme 2. Synthesis of 3-bromo-8-hydroxy-4-oxo-4H-chromen-7-yl 
α-D-arabinofuranoside 15. (a) AcOH, BF3·OEt2, 90∼100oC, 4 h, 96%. (b) HC(OEt)3, 
70% HClO4, 85 oC, 12 h, 82%. (c) i) CH3(CH2)4COCl, pyridine, 0 oC-rt, 16 h; ii) 
PhSH, imidazole, NMP, 0 oC-rt, 3 h, 70%. (d) 3, BF3·OEt2, CH2Cl2, 4 Å MS, rt, 62%. 
(e) PhI(OAc)2, TMSBr, CH2Cl2, pyridine, 0 oC-rt, 67%. f) K2CO3, MeOH/THF/H2O 
(2:1:0.2), rt, 77%. 
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Scheme 3. Synthesis of 3-bromo-5-hydroxy-4-oxo-4H-chromen-7-yl 
α-D-arabinofuranoside 21. (a) Ac2O, BF3·OEt2, rt, 34 h; (b) MsCl, DMF, BF3·OEt2, 
50oC, 4 h, 37%. (c) i) CH3(CH2)4COCl, pyridine, 0 oC–rt, 16 h; ii) PhSH, imidazole, 
NMP, 0 oC-rt, 3 h, 64%. (d) 3, BF3·OEt2, CH2Cl2, 4 Å MS, rt, 89%. (e) PhI(OAc)2, 
TMSBr, CH2Cl2, pyridine, 0 oC–rt, 63%. (f) K2CO3, MeOH/THF/H2O (2:1:0.2), rt, 
42%. 
 
Thus, acylation of pyrogallol with glacial acetic acid under the action of 
BF3·OEt2 at 90∼100oC provided ketone 10, which was treated with triethyl 
orthoformate in the presence of 70% HClO4 to afford chromone 11   (Scheme 2). 
Selective protection of the 5-OH in diol 11 was achieved via 5,7-di-O-hexanoate 
formation and subsequent removal of the 7-O-acyl group,[12] which is para to the 
electron-withdrawing pyrone carbonyl function, with PhSH and imidazole in 
N-methyl pyrolidinone (NMP) to give 12 (70% for two steps). Glycosylation of 
phenol 12 with 2,3,5-tri-O-acetyl-D-arabinofuranosyl trichloroacetimidate (3) under 
the promotion of BF3·OEt2 led to the α-glycoside 13 in 62% yield. Bromination of 
compound 13 was achieved with PhI(OAc)2 and TMSBr at room temperature with 
pyridine as a base,[19] affording chromone 3-bromide 14. Removal of the acyl 
protecting groups in 14 with K2CO3 in a mixed solvent of MeOH/THF/H2O, to 
compromise the solubility of the reactants, provided the desired 
7-α-D-arabinofuranosyloxy-chromon-3-bromide 15. 
Employing a similar procedure described above, the A ring isomer 21 was 
synthesized with phloroglucinol as the starting material (Scheme 3). Worth noting is 
that the glycosylation of the 5-O-hexanoyl-7-ol 18 with arabinofuranosyl 
 5
trichloroacetimidate 3 gave the glycoside 19 in a much better 89% yield comparing to 
the glycosylation of 8-O-hexanoyl-7-ol 12 with imidate 3 (and the glycosylation of 
the isoflavone derivative 8 as well, Scheme 1) under similar conditions (62%). The 
latter reaction suffered from the migration of the 8-O-hexanoyl group onto the 
neighboring 7-OH under the glycosylation conditions as mentioned. 
 
Although Suzuki-Miyaura reaction has been widely used as one of the most 
efficient methods for C-C bond formation,[18] in only few examples flavonoid iodides 
or O-triflates have been employed as the coupling partners.[20] In fact, the instability 
of the 4H-pyranones under basic conditions limited the choice of bases in the 
Suzuki-Miyaura coupling of bromides 15 and 21 with boronic acids. Under the 
optimized conditions with 2-(2,6-dimethoxybiphenyl)dicyclohexylphosphine (SPhos) 
as a ligand, as introduced by Buchwald et al,[21] in the presence of Pd(OAc)2 and 
K2CO3, coupling of bromide 15 with a variety of the aryl boronic acids provided the 
corresponding isoflavone glycosides 22a-n in moderate yields (Table 1). Reduction of 
the bromide and degradation of the chromone B ring are the major side reactions. 
 
Table 1. Synthesis of the B-ring congeners (22) via Suzuki-Miyaura coupling of 15. 
O
O
O
O
HO OH
HO
OH
Br
B(OH)2
+
Pd(OAc)2/SPhos
K2CO3, 50℃
Acetone-H2O
O
O
O
O
HO OH
HO
OH
R
R15 22
 
Product R Yield (%) 
22a H 65 
22b 4-OMe 54 
22c 2-OMe 50 
22d 3-OMe 75 
22e 4-Me 45 
22f 2-Me 34 
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22g 3-Me 58 
22h(1) 4-OH 48 
22i 3-OH 35 
22j 4-F 31 
22k 4-NMe2 36 
22l 4-NHBoc 39 
22m 4-CF3 41 
22n 4-SiMe3 30 
 
Under similar conditions, the couplings with chromon-3-bromide 21 gave 
lower yields of the desired product (Table 2), because chromone 21 was found more 
vulnerable to basic degradation than its region-isomer 15. An alternative procedure for 
this coupling was in the absence of ligand and with NaOAc as a base, but the coupling 
yields were even lower. 
 
Table 2. Synthesis of the A,B-ring congeners (23) via Suzuki coupling of 21. 
O
O
O
O
HO OH
HO
Br
B(OH)2
+
O
O
O
O
HO OH
HO
R
R
23
OH OH
21
A or B
 
Entry R Conditions Yield (%) 
A 28 
23a H 
B 16 
23b 4-OMe A 43 
23c 2-OMe A 39 
23d 3-OMe A 19 
23e 4-Me B 39 
23f 3-Me A 16 
A 39 
23g 4-OH 
B 12 
23h 3-OH A 35 
Conditions A: Pd(OAc)2 (0.05 equiv), SPhos (0.15 equiv), K2CO3 (3.0 equiv), 
acetone/H2O, 50 oC. Conditions B: Pd(OAc)2 (0.05 equiv), NaOAc (3.0 equiv), MeOH, 
reflux. 
 
Inhibitory activities against α-glucosidases 
The synthetic natural product 1 exhibited potent inhibitory activity against the 
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α-glucosidases of rat liver microsome, with an IC50 = 18 nM, that is comparable to the 
literature value of 14 nM.[11b] However, none of the stereoisomers (9a-d) showed 
remarkable activities at concentrations up to 10 μM. Gratifyingly, all the B ring 
analogs of 1 (22a-n) exhibited activities at 10 nM concentration (Table 3). The 4-OH 
in the B ring of 1 could be replaced by -OMe, -H, -F, -Me, and -CF3 without 
considerably affecting the activity. Their regio-isomers, i.e., the 3-OH, 2-OMe, 
3-OMe, 2-Me, and 3-Me derivatives, were similarly potent. Especially, the 3-OMe 
and 4-NMe2 derivatives (22d and 22l) were about 3–fold more potent that the 4’-OH 
natural product (1). However, the 5-OH (on the A ring) derivatives, which are 
regio-isomers of the above 8-OH isoflavone glycosides (22a-n) were 1000 times less 
potent inhibitiors. Worth of noting is that all these compounds, including the natural 
flavone glycoside 1, were found inert toward the α-glucosidase from bakers yeast. 
 
Table 3. Inhibitory activities of the isoflavone 7-O-α-D-arabinofuranosides 22 and 23 
against the α-glucosidases of rat liver microsome. 
O
OH
O
O
O
OHHO
OH
R
22
O O
O
O
OHHO
OH
ROH
23  
R Compound (IC50, in μM) 
H 22a (0.040) 23a (10) 
4-OMe 22b (0.022) 23b (8) 
2-OMe 22c (0.015) 23c (10) 
3-OMe 22d (0.006) 23d (10) 
4-Me 22e (0.035) 23e (7) 
2-Me 22f (0.020) - 
3-Me 22g (0.050) 23f (5) 
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4-OH 22h/1 (0.018) 23g (15) 
3-OH 22i (0.017) 23h (33% at 50) 
4-F 22j (0.015) - 
4-NMe2 22k (0.008) - 
4-NHBoc 22l (0.020) - 
4-CF3 22m (0.030) - 
4-SiMe3 22n (35% at 0.050) - 
 
Conclusions 
A concise approach to the synthesis of isoflavone glycosides has been 
developed, where the Suzuki-Miyaura coupling between glycosyloxy 
chromon-3-bromides (i.e., 15 and 21) and aryl boronic acids is employed as the final 
step. Although there remains room for increasing the coupling yields, and the 
glycosylation yields as well, the present method provides a quick and divergent access 
to this type of common natural products. Totally 26 isoflavone glycosides (9a-d, 
22a-n, and 23a-h) have been readily synthesized, which are analogs of the potent 
α-glucosidase inhibitor A-76202 with minor variations at the sugar moiety, the A, and 
B rings. Evaluation of the inhibitory activities of these compounds against the 
α-glucosidases of rat liver microsome has led to a preliminary and clear SAR 
(structure-activity relationship) conclusion: the stereochemistry of the sugar moiety 
(the α-D-arabinofuranosyl unit) and the 8-hydroxyl group in the A ring are crucial to 
the activity, while variations on the B ring of the isoflavone 7-O-glycosides are 
largely tolerated to retain the potent α-glucosidase inhibitory activities. 
 
Experimental 
General methods[12] 
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General procedure for assay of the α-glucosidase inhibitory activity 
IC50 value was determined at 37 oC in 0.1 M K2HPO4/KH2PO4-0.15M KCl buffer (pH 
6.8), with p-nitrophenyl α-D-glucopyranoside (purchased from Sigma Chemical Co.) 
as the substrate. Rat liver microsome fraction solubilized with 25% Triton X-100 was 
used as enzyme. The inhibitor (5 µL, in DMSO), diluted enzyme solution (20 µL), 
and buffer solution (105 µL) were added to a 96-well microtiter plate, and 
preincubated for 10 min at 37 oC. The enzymatic reaction was started by the addition 
of 20 µL of the substrate solution (20 mM). The absorption at 400 nm was measured 
immediately. The increase of absorption per min at 400 nm was taken as the relative 
rate for the hydrolysis of the substrate. The increase was linear during all 
measurements (30 min). IC50 values were determined by plotting the relative rate of 
the substrate hydrolysis vs. the inhibitor concentration. The inhibitor concentration 
corresponding to half of the relative rate measured in the absence of the inhibitor gave 
the appropriate IC50 value. All the experiments were carried out in triplicate. 
Synthesis of 4’,8-dihydroxyisoflavon-7-yl pentoses (1 and 9a-d) 
General procedure: BF3·OEt2 (0.1 M in CH2Cl2, 0.4 mL) was added slowly to a 
solution of 8 (100 mg, 0.214 mmol) and glycosyl trichloroacetimidate (250 mg, 0.612 
mmol) in dried CH2Cl2 (8 mL) in the presence of newly activated 4 Å molecular 
sieves at 0 oC. The mixture was allowed to warm up to rt and stirred until TLC 
indicated the completion of the reaction. The solid in the mixture was filtered off by 
passing it through a celite pad and the filtrate was condensed in vacuo. The residue 
was dissolved in MeOH/THF/H2O (2 : 1 : 0.2, 5 mL) and K2CO3 (119 mg, 0.856 
mmol) was added. The mixture was stirred at rt until TLC indicated the completion of 
the reaction. Dowex-50 (H+) resin was used to neutralize the reaction mixture. The 
solution was filtered, and the filtrate was concentrated. The residue was purified by 
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silica gel column chromatography (CH2Cl2/MeOH, 10:1) to yield 1 or 9 as a white 
solid. 
4’,8-Dihydroxyisoflavon-7-yl α-D-arabinofuranoside (1, A-76202): Yield = 58%. Rf 
0.24 (CH2Cl2 : MeOH = 10 : 1); 1H NMR (300 MHz, CD3OD): δ = 8.22 (s, 1 H), 7.64 
(d, J = 9.0 Hz, 1 H), 7.37 (d, J = 8.7 Hz, 2 H), 7.31 (d, J = 9.0 Hz, 1 H), 6.84 (d, J = 
8.7 Hz, 2 H), 5.74 (s, 1 H), 4.37 (d, J = 1.5 Hz, 1 H), 4.16 (dd, J = 8.7 Hz, 4.5 Hz, 1 
H), 4.07 (m, 1 H), 3.74 (dd, J = 11.7 Hz, 3.6 Hz, 1 H), 3.69 (dd, J = 11.7 Hz, 5.1 Hz, 1 
H); 13C NMR (75 MHz, CD3OD): δ = 178.5, 159.1, 157.7, 154.6, 153.2, 131.8, 126.2, 
124.4, 123.1, 119.3, 116.6, 116.3, 110.0, 90.1, 82.4, 79.0, 63.5. 
4’,8-Dihydroxyisoflavon-7-yl α-L-arabinofuranoside (9a): Yield = 26%. Rf 0.38 
(CH2Cl2 : MeOH = 10 : 1); [α]D22 = -106.2 (c 0.56, MeOH); 1H NMR (300 MHz, 
CD3OD): δ = 8.21 (s, 1 H), 7.85 (d, J = 9.0 Hz, 1 H), 7.37 (d, J = 8.7 Hz, 2 H), 7.00 (d, 
J = 9.0 Hz, 1 H), 6.84 (d, J = 8.7 Hz, 2 H), 5.90 (s, 1 H), 4.40 (s, 1 H), 4.30 (dd, J = 
7.8 Hz, 4.5 Hz, 1 H), 4.10 (br s, 1 H), 3.67-3.62 (m, 2 H); ESI-MS (m/z): 403.1 (M + 
H+); HRMS (ESI) calcd for C20H19O9+ 403.1024, Found: 403.1024. 
4’,8-Dihydroxyisoflavon-7-yl β-D-ribofuranoside (9b): Yield = 60%. Rf 0.14 
(CH2Cl2 : MeOH = 10 : 1); [α]D23 = -107.6 (c 0.24, MeOH); 1H NMR (300 MHz, 
DMSO-d6): δ = 9.59 (br s, 1 H), 8.41 (s, 1 H), 7.55 (d, J = 9.0 Hz, 1 H), 7.41 (d, J = 
8.7 Hz, 2 H), 7.24 (d, J = 9.0 Hz, 1 H), 6.83 (d, J = 8.7 Hz, 2 H), 5.52 ( s, 1 H), 5.05 
(d, J = 6.0 Hz, 1 H), 4.30-4.10 (m, 2 H), 3.94 (br s, 1 H), 3.61 (dd, J = 12.0 Hz, 1.8 Hz, 
1 H), 3.44 (dd, J = 12.0 Hz, 6.0 Hz, 1 H); 13C NMR (75 MHz, DMSO-d6): δ = 175.4, 
157.4, 153.4, 148.1, 146.3, 136.4, 130.4, 123.5, 122.7, 120.0, 115.3, 115.2, 115.16, 
115.10, 107.2, 84.9, 74.7, 70.2, 62.2; ESI-MS (m/z): 403.2 (M + H+), HRMS (ESI) 
calcd for C20H19O9+ 403.1024, Found: 403.1023. 
4’,8-Dihydroxyisoflavon-7-yl β-D-xylofuranoside (9c): Yield = 46%. Rf 0.20 
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(CH2Cl2 : MeOH = 10 : 1); [α]D22 = -100.2 (c 0.21, MeOH); 1H NMR (300 MHz, 
DMSO-d6): δ = 9.45 (br s, 1 H), 8.38 (s, 1 H), 7.55 (d, J = 9.0 Hz, 1 H), 7.41 (d, J = 
8.4 Hz, 2 H), 7.28 (d, J = 9.0 Hz, 1 H), 6.82 (d, J = 8.4 Hz, 2 H), 5.57 (s, 1 H), 4.31 (s, 
1 H), 4.21 (dd, J = 11.1, 4.8 Hz, 1 H), 4.07 (dd, J = 4.5, 1.5 Hz, 1 H), 3.70 (dd, J = 
11.7, 4.8 Hz, 1 H), 3.53 (dd, J = 11.7, 6.6 Hz, 1 H); 13C NMR (75 MHz, DMSO-d6): δ 
= 175.2, 157.2, 153.1, 147.2, 145.9, 137.3, 130.1, 123.4, 122.6, 120.1, 115.6, 115.0, 
107.7, 84.6, 80.3, 75.0, 60.1; ESI-MS (m/z): 401.3 (M - H+); HRMS (ESI) calcd for 
C20H19O9+ 403.1024, Found: 403.1023. 
4’,8-Dihydroxyisoflavon-7-yl β-D-xylopyranoside (9d): Yield: 76%. Rf 0.20 (DCM : 
MeOH = 10 : 1); [α]D21 = - 33.8 (c 0.29 , MeOH); 1H N MR 300 MHz CD3OD（ ， ）δ 
= 8.21 (s, 1 H), 7.63(d, J = 8.7 Hz, 1 H), 7.37 (d, J = 7.8 Hz, 2 H), 7.25 (d, J = 8.7 Hz, 
1 H), 6.84 (d, J = 7.8 Hz, 2 H), 4.96 (d, J = 7.8 Hz, 1 H), 3.90 (dd, J = 11.1 Hz, 4.8 Hz, 
1 H), 3.60-3.36 (m, 4 H); 13C NMR 75 MHz CD3OD（ ， ）δ = 178.7, 159.0, 155.2, 
150.2, 148.3, 137.6, 131.7, 126.0, 124.4, 121.8, 117.0, 116.5, 115.8, 104.2, 77.5, 74.8, 
71.2, 67.3; ESI-MS (m/z): 401.1 (M – H+); HRMS (ESI) calcd for C20H18O9Na+ 
425.0843, Found: 425.0813. 
Synthesis of 3-bromo-8-hydroxy-4-oxo-4H-chromen-7-yl α-D-arabinofuranoside 
(15) 
1-(2,3,4-Trihydroxyphenyl)ethanone (10): A solution of pyrogallol (12.61 g, 100 
mmol) and glacial acetic acid (64 mL, 110.9 mmol) in BF3·OEt2 (37 mL) was heated 
at 90-100 oC for 4 h in the protection of argon, cooled, and then poured into 10% 
NaOAc (600 mL), and stirred overnight. The dark solution was extracted with ether (3 
× 300 mL). The organic layer was washed with saturated NaCl and dried with 
anhydrous Na2SO4. Removal of the solvent gave 10 (16.1 g, 96%) as a yellow solid. 
Rf 0.69 (CH2Cl2 : MeOH = 10 : 1).  
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7,8-Dihydroxy-4H-chromen-4-one (11): Compound 10 (10.0g, 59.47 mmol) was 
suspended in ethyl orthoformate (50 mL, 300 mmol) and was treated with 70% HClO4 
(6 mL) slowly. The mixture was heated on an oil bath at 85 oC for 12 h, and was then 
cooled, and 200 mL ether was added. The precipitate was filtered off, washed with 
water, and dried, giving crude 11 (8.72 g, 82%) as yellow solid. Rf 0.45 (CH2Cl2 : 
MeOH =10 : 1). 
7-Hydroxy-4-oxo-4H-chromen-8-yl hexanoate (12): Hexanoyl chloride (27 mL, 
195.6 mmol) was added to a stirring solution of 11 (6.8 g, 38.2 mmol) in pyridine at 0 
oC, the mixture was allowed to warm up to rt. After stirring for an additional 16 h, the 
solution was diluted with CH2Cl2, and then was washed with 1 N aq. HCl and 
saturated NaCl. The organic layer was dried with anhydrous Na2SO4, and then 
concentrated in vacuum. The resulting residue was dissolved into dried NMP (60 mL). 
Imidazole (1.10 g, 15.84 mmol) was added and the solution was cooled to 0 oC by an 
ice-water bath, followed by the addition of PhSH (5.8 mL, 56.94 mmol). The reaction 
mixture was stirred and allowed to warm up to rt naturally. When TLC indicated the 
completion of the reaction, CH2Cl2 (300 mL) was added, the resulting mixture was 
washed with 1 N aq. HCl, water, and saturated NaCl sequentially. The organic layer 
was dried with anhydrous Na2SO4, and concentrated in vacuum. The residue was 
purified by silica gel column chromatography (petroleum ether : EtOAc = 2 : 1) to 
yield 12 as a yellow solid (7.64 g, 70% for two steps). Rf 0.17 (petroleum ether : 
EtOAc = 2 : 1); 1H NMR (300 MHz, CDCl3): δ = 8.28 (br s, 1 H), 7.98 (d, J = 9.0 Hz, 
1 H), 7.79 (d, J = 5.7 Hz, 1 H), 7.11 (d, J = 9.0 Hz, 1 H), 6.32 (d, J = 5.7 Hz, 1 H), 
2.71 (t, J = 7.5 Hz, 2 H), 1.82 (p, J = 7.2 Hz, 2 H), 1.48-1.35 (m, 4 H), 0.93 (t, J = 6.9 
Hz, 3 H). 
8-(Hexanoyloxy)-4-oxo-4H-chromen-7-yl 2,3,5-tri-O-acetyl-α-D-arabino 
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furanoside (13): A solution of 12 (7.64 g, 27.65 mmol) and glycosyl imidate 3 (17.86 
g, 42.46 mmol) in dried CH2Cl2 (200 mL) was treated with newly activated 4 Å MS 
and stirred at rt for 15 min. BF3·OEt2 (2.8 mL, 2.80 mmol) was added dropwise to the 
solution at 0 oC, and the reaction mixture was stirred at rt for 3 h, and then Et3N (5 mL) 
was added to quench the reaction. The solid was filtered off by passing the reaction 
through a celite pad and the solvent was removed in vacuum. The residue was purified 
by silica gel column chromatography (petroleum ether : EtOAc = 2 : 1) to yield 13 as 
a yellows syrup (9.1g, 62%). Rf 0.53 (petroleum : EtOAc =1 : 1); 1H NMR (300 MHz, 
CDCl3): δ = 8.05 (d, J = 9.0 Hz, 1 H), 7.78 (d, J = 6.3 Hz, 1 H), 7.31 (d, J = 9.0 Hz, 1 
H), 6.30 (d, J = 6.3 Hz, 1 H), 5.79 (s, 1 H), 5.38 (s, 1 H), 5.11 (br s, 1 H), 4.47-4.35 
(m, 2 H), 4.28 (dd, J =11.7 Hz, 4.5 Hz, 1 H), 2.68 (t, J = 7.8 Hz, 2 H), 2.16 (s, 3 H), 
2.14 (s, 3 H), 2.11 (s, 3 H), 1.84 (q, J = 7.5 Hz, 2 H), 1.51-1.30 (m, 4 H), 0.96 (t, J = 
6.6 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 176.4, 170.5, 170.4, 169.9, 169.4, 
154.8, 152.0, 149.9, 128.8, 123.6, 120.7, 113.8, 113.0, 104.5, 82.0, 81.1, 76.7, 62.7, 
33.7, 31.2, 24.6, 22.2, 20.7, 20.6, 13.9; ESI-MS (m/z): 535.3 (M + H+), 557.3 (M + 
Na+); HRMS (MALDI) calcd for C26H30O12Na+ 557.1630, Found 557.1638. 
3-Bromo-8-(hexanoyloxy)-4-oxo-4H-chromen-7-yl 
2,3,5-tri-O-acetyl-α-D-arabinofuranoside (14): TMSBr (8.6 mL, 64.96 mmol) was 
added slowly to a solution of PhI(OAc)2 (10.6 g, 32.71 mmol) in dry CH2Cl2 (50 mL) 
at 0 oC, and the solution was stirred in an ice-bath for 45 min before the addition of 13 
(5.8 g, 10.85 mmol) in CH2Cl2 (25 mL). The ice-bath was removed and the reaction 
mixture was allowed to warm up to rt and stayed 2 h. Pyridine (5.7 mL, 66.47 mmol) 
was then added, and the stirring was continued for an additional 1 h. The resulting 
mixture was diluted with CH2Cl2, and washed with saturated Na2S2O3 and saturated 
NaCl. The organic layer was dried with anhydrous Na2SO4, and concentrated in 
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vacuum. The residue was purified by silica gel column chromatography (petroleum 
ether : EtOAc = 3 : 1 to 5 : 2) to yield 14 as a yellow syrup (4.5 g, 67%). Rf 0.85 
(petroleum ether : EtOAc = 1 : 1); 1H NMR (300 MHz, CDCl3): δ = 8.15 (s, 1 H), 
8.11 (d, J = 9.0 Hz, 1 H), 7.35 (d, J = 9.0 Hz, 1 H), 5.80 (s, 1 H), 5.38 (s, 1 H), 5.12 (d, 
J = 3.6 Hz, 1 H), 4.47-4.36 (m, 2 H), 4.28 ( dd, J = 11.1 Hz, 4.5 Hz, 1H), 2.68 (t, J = 
7.5 Hz, 2 H), 2.16 (s, 3 H), 2.14 (s, 3 H), 2.11 (s, 3 H), 1.83 (q, J = 7.2 Hz, 2 H), 
1.48-1.35 (m, 4 H), 0.96 (t, J = 6.6 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 171.2, 
170.4, 170.38, 169.9, 169.4, 153.2, 152.3, 149.6, 128.6, 124.2, 118.8, 114.5, 110.9, 
104.5, 82.2, 81.1, 76.7, 62.7, 33.7, 31.2, 24.6, 22.2, 20.7, 20.62, 20.60, 13.9;  ESI-MS 
(m/z): 613.1 (M + H+), 635.2 (M + Na+); HRMS (MALDI) calcd for C26H29O12BrNa+ 
635.0735, Found: 635.0721. 
3-Bromo-8-hydroxy-4-oxo-4H-chromen-7-yl α-D-arabinofuranoside (15): The 
chromone derivative 14 (585 mg, 0.954 mmol) in MeOH/THF/H2O (2 : 1 : 0.2, 50 mL) 
was treated with K2CO3 (527 mg, 3.82 mmol) at rt for 10 h. TLC indicated the 
completion of the reaction. Dowex-50 (H+) was added to neutralize the mixture. The 
solvent was removed in vacuum. Flash chromatography of the residue on silica gel 
yielded 15 as a yellow solid (287 mg, 77%). Rf 0.41 (CH2Cl2 : MeOH = 10 : 1); [α]D24 
= 74.7 (c 0.20, MeOH); 1H NMR (300 MHz, CD3OD): δ = 8.57 (s, 1 H), 7.56 (d, J = 
9.0 Hz, 1 H), 7.33 (d, J = 9.0 Hz, 1 H), 5.72 (s, 1 H), 4.36 (d, J = 2.1 Hz, 1 H), 4.13 
(dd, J = 9.0 Hz, 4.5 Hz, 1 H), 4.08 (m, 1 H), 3.75 (dd, J = 11.7 Hz, 3.6 Hz, 1 H), 3.70 
(dd, J = 11.7 Hz, 5.1 Hz, 1 H); ESI-MS (m/z): 410.8 (M + Na+). 
Synthesis of 3-Bromo-5-hydroxy-4-oxo-4H-chromen-7-yl α-D-arabinofuranoside 
(21) 
1-(2,4,6-Trihydroxyphenyl)ethanone (16): A solution of phloroglucinol (25.0 g, 198 
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mmol) and Ac2O (190 mL, 199.5 mmol) in BF3·OEt2 (75 mL) was stirred at rt for 34 h, 
before it was poured into 10% NaOAc (700 mL) and stirred overnight. The precipitate 
was filtered off, washed with water and dried to give the crude 16 (24 g) as a yellow 
solid. Rf 0.74 (CH2Cl2 : MeOH =5 : 1). 
5,7-Dihydroxy-4H-chromen-4-one (17): Newly distilled BF3·OEt2 (50 mL, 0.54 mol) 
was added slowly to a solution of 16 (20.2 g, 0.12 mmol) in dried DMF (180 mL) in 1 
h at rt. Then the reaction was transferred to an oil-bath of 50 oC before the addition of 
a solution of MsCl (32 mL, 0.4 mol) in dried DMF (72 mL, 0.9 mol). The mixture 
was stirred at 50 oC for 4 h, and then cooled and poured into 2 L ice-water. The black 
solid was filtered off and the filtrate was extracted with EtOAc. Evaporation of the 
solvent and purification of the residue by flash chromatography (CH2Cl2 : MeOH =10: 
1) yielded yellow solid 17 (8.0 g, 37% for two steps). Rf 0.90 (CHCl3 : MeOH = 10: 1); 
1H NMR (300 MHz, DMSO-d6): δ = 12.07 (br s, 1 H), 10.92 (br s, 1 H), 8.18 (d, J = 
6.0 Hz, 1 H), 6.38 (d, J = 2.1 Hz, 1 H), 6.28 (d, J = 6.0 Hz, 1 H), 6.21 (d, J = 2.1 Hz, 1 
H). 
7-Hydroxy-4-oxo-4H-chromen-5-yl hexanoate (18): A similar procedure to the 
synthesis of 12 was employed. Yield = 64%; Rf  0.21 (petroleum ether : EtOAc=3 : 1); 
1H NMR (300 MHz, CDCl3): δ = 10.97 (br s, 1 H), 7.67 (d, J = 9.0 Hz, 1 H), 7.78 (d, 
J = 2.4 Hz, 1 H), 6.59 (d, J = 2.4 Hz, 1 H), 6.09 (d, J = 9.0 Hz, 1 H), 2.71 (t, J = 7.5 
Hz, 2 H), 1.80 (m, 2 H), 1.50-1.33 (m, 4 H), 0.94 (t, J = 6.9 Hz, 3 H). 
5-(Hexanoyloxy)-4-oxo-4H-chromen-7-yl 2,3,5-tri-O-acetyl-α-D-arabino- 
furanoside (19): A similar procedure to the synthesis of 13 was employed. Yield = 
89%. Rf  0.38 (petroleum ether : EtOAc=2 : 1); 1H NMR (300 MHz, CDCl3): δ = 7.70 
(d, J = 6.0 Hz, 1 H), 7.00 (d, J = 2.1 Hz, 1 H), 6.72 (d, J = 2.1 Hz, 1 H), 6.16 (d, J = 
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6.0 Hz, 1 H), 5.77 (s, 1 H), 5.37 (s, 1 H), 5.11 (d, J = 4.5 Hz, 1 H), 4.47-4.35 (m, 2 H), 
4.29 (dd, J = 11.4 Hz, 4.8Hz, 1 H), 2.71 (t, J = 7.8 Hz, 2 H), 2.16 (s, 3 H), 2.15 (s, 3 
H), 2.12 (s, 3 H), 1.80-1.70 (m, 2 H), 1.45-1.30 (m, 4 H), 0.93 (t, J = 6.6 Hz, 3 H); 13C 
NMR (75 MHz, CDCl3): δ = 175.7, 172.3, 170.5, 170.1, 169.5, 159.5, 158.7, 153.9, 
150.8, 113.9, 113.5, 109.9, 103.8, 102.1, 82.2, 81.1, 76.7, 62.8, 34.2, 31.3, 24.1, 22.4, 
20.73, 20.68, 20.65, 13.9;  ESI-MS (m/z): 557.3 (M + Na+); HRMS (MALDI) calcd 
for C26H30O12Na+ 557.1630, Found 557.1638. 
3-Bromo-5-(hexanoyloxy)-4-oxo-4H-chromen-7-yl 
2,3,5-tri-O-acetyl-α-D-arabinofuranoside (20): A similar procedure to the synthesis 
of 14 was employed. Yield = 63%. Rf 0.55 (petroleum ether : EtOAc = 2 : 1). 1H 
NMR (300 MHz, CDCl3): δ = 8.10 (s, 1 H), 7.02 (d, J = 1.2 Hz, 1 H), 6.77 (d, J = 1.2 
Hz, 1 H), 5.77 (s, 1 H), 5.38 (s, 1 H), 5.12 (d, J = 4.5 Hz, 1 H), 4.48-4.35 (m, 2 H), 
4.27 (dd, J = 11.4 Hz, 4.8 Hz, 1 H), 2.75 (t, J = 7.5 Hz, 2 H), 2.16 (s, 3 H), 2.15 (s, 3 
H), 2.12 (s, 3 H), 1.77 (q, J = 6.9 Hz, 2 H), 1.45-1.30 (m, 4 H), 0.93 (t, J = 6.6 Hz, 3 
H); 13C NMR (75 MHz, CDCl3): δ = 172.3, 170.5, 170.1, 169.9, 169.5, 159.8, 158.3, 
152.5, 150.9, 111.6, 110.6, 103.9, 102.0, 82.3, 81.1, 76.6, 62.8, 57.9, 34.1, 31.3, 24.1, 
22.4, 20.75, 20.70, 20.66, 13.9; ESI-MS (m/z): 635.2 (M + Na+); HRMS (MALDI) 
calcd for C26H29O12BrNa+ 635.0735, Found: 635.0720. 
3-Bromo-5-hydroxy-4-oxo-4H-chromen-7-yl α-D-arabinofuranoside (21): A 
similar procedure to the synthesis of 15 was employed. Yield = 42%. Rf 0.47 (CH2Cl2 : 
MeOH = 10 : 1); [α]D24 = 117.6 (c 0.28, MeOH); 1H NMR (300 MHz, CD3OD): δ = 
8.47 (s, 1 H), 6.70 (d, J = 1.8 Hz, 1 H), 6.54 (d, J = 1.8 Hz, 1 H), 5.65 (d, J = 1.5 Hz, 
1 H), 4.30 (dd, J = 3.9, 1.5 Hz, 1 H), 4.08 (m, 1 H), 4.03 (dd, J = 6.0 Hz, 3.9 Hz, 1 H), 
3.80 (dd, J = 12.0, 2.7 Hz, 1 H), 3.70 (dd, J = 12.0, 4.8 Hz, 1 H); 13C NMR (75 MHz, 
CD3OD): δ = 178.2, 165.0, 163.0, 159.3, 157.3, 108.9, 108.2, 107.2, 102.0, 96.5, 87.4, 
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83.9, 78.5, 63.0; ESI-MS (m/z): 410.8 (M + Na+). 
Suzuki-Miyaura coupling 
General procedure A: Pd(OAc)2 (1.5 mg, 0.0067 mmol), SPhos (8.0 mg, 0.0195 
mmol), and K2CO3 (54 mg, 0.390 mmol) were added to a solution of 
3-bromochromone 15 or 21 (50 mg, 0.129 mmol) and aryl boronic acid (0.195 mmol) 
in acetone-H2O (1:1, 1.0 mL) under the protection of argon. The mixture was stirred 
in an oil-bath at 50 oC until TLC indicated the disappearance of the starting material 
(15 or 21). The reaction solution was then filtered through a silica pad (300~400 mesh) 
and the filtrate was concentrated in vacuum to give a residue, which was purified by 
preparative TLC (CH2Cl2 : MeOH = 8 : 1) to yield the coupling products. The yields 
are given in Tables 1 and 2. 
General procedure B: Pd(OAc)2 (1.5 mg, 0.0067 mmol), SPhos (8.0 mg, 0.0195 
mmol, 0.15 eq.), and NaOAc (32 mg, 0.390 mmol) were added to a solution of 
3-bromochromone 21 (50 mg, 0.129 mmol) and aryl boronic acid (0.195 mmol) in 
methanol (0.5 mL) under the protection of argon. The mixture was refluxed in an 
oil-bath until TLC indicated the disappearance of 21. Similar workup procedure as 
given in the General procedure A provided the coupling products. The yields are given 
in Table 2. 
8-Hydroxyisoflavon-7-yl α-D-arabinofuranoside (22a): Rf  0.29 (CHCl3 : MeOH = 
10 : 1); [α]D24 = 31.8 (c 0.11, MeOH); 1H NMR (300 MHz, CD3OD): δ = 8.26 (s, 1 H), 
7.62 (d, J = 9.0 Hz, 1 H), 7.52 (d, J = 6.3 Hz, 2 H), 7.43-7.35 (m, 3 H), 7.31 (d, J = 
9.0 Hz, 1 H), 5.73 ( s, 1 H), 4.37 (br s, 1 H), 4.16 (dd, J = 8.7 Hz, 4.5 Hz, 1 H), 4.06 
(m, 1 H), 3.73 (dd, J = 11.7 Hz, 3.6 Hz, 1 H), 3.68 ( dd, J = 11.7 Hz, 5.4 Hz, 1 H); 13C 
NMR (75 MHz, CD3OD): δ = 178.5, 155.9, 149.7, 148.3, 138.0, 133.6, 130.6, 129.7, 
129.4, 126.1, 121.4, 116.8, 115.8, 109.1, 88.7, 83.0, 78.9, 63.3; ESI-MS (m/z): 387.2 
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(M + H+), 409.2 (M + Na+), 425.0 (M + K+); HRMS (MALDI) calcd for C20H18O8Na+ 
409.0894, Found: 409.0902. 
8–Hydroxy-4'-methoxyisoflavon-7-yl α-D-arabinofuranoside (22b): Rf 0.29 
(CHCl3 : MeOH = 10 : 1); [α]D24 = 142.4 (c 0.10, MeOH); 1H NMR (300 MHz, 
CD3OD): δ = 8.29 (s, 1 H), 7.66 (d, J = 8.7 Hz, 1 H), 7.50 (d, J = 8.4 Hz, 2 H), 7.35 (d, 
J = 8.7 Hz, 1 H), 7.01 (d, J = 8.4 Hz, 2 H), 5.77 (s, 1 H), 4.41 (br s, 1 H), 4.18 (dd, J = 
8.7 Hz, 4.5 Hz, 1 H), 4.10 (m, 1 H), 3.85 (br s, 3 H), 3.77 (dd, J = 11.7 Hz, 3.6 Hz, 1 
H), 3.73 (dd, J = 11.7 Hz, 5.1 Hz, 1 H); 13C NMR (75 MHz, CD3OD): δ = 178.8, 
161.5, 155.4, 149.6, 148.4, 138.1, 131.7, 125.74, 125.71, 121.4, 116.7, 115.8, 115.2, 
109.1, 88.8, 83.0, 78.9, 63.3, 56.1; ESI-MS (m/z): 417.0 (M + H+), 439.0 (M + Na+), 
455.0 (M + K+); HRMS (MALDI) calcd for C21H20O9Na+ 439.1000, Found: 439.0999. 
8–Hydroxy-2'-methoxyisoflavon-7-yl α-D-arabinofuranoside (22c): Rf  0.29 
(CHCl3 : MeOH = 10 : 1); [α]D24 = 74.2 (c 0.12, MeOH); 1H NMR (300 MHz, 
CD3OD): δ = 8.54 (br s, 1 H), 8.13 (s, 1 H), 7.37 (t, J = 7.8 Hz, 1 H), 7.33 (d, J = 8.7 
Hz, 1 H), 7.28-7.19(m, 2 H), 7.05 (d, J = 8.7 Hz, 1 H), 6.99 (t, J = 7.8 Hz, 1 H), 5.68 
(s, 1 H), 4.39 (br s, 1 H), 4.19 (dd, J = 8.7 Hz, 4.5 Hz, 1 H), 4.00 (m, 1 H), 3.77 (br s, 
4 H), 3.70 (dd, J = 11.7 Hz, 5.4 Hz, 1 H); ESI-MS (m/z): 439.0 (M + Na+); HRMS 
(MALDI) calcd for C21H20O9Na+ 439.1000, Found: 439.0990. 
8-Hydroxy-3’-methoxyisoflavon-7-yl α-D-arabinofuranoside (22d): Rf  0.29 
(CHCl3 : MeOH = 10 : 1); [α]D24 = 27.6 (c 0.13, MeOH); 1H NMR (300 MHz, 
CD3OD): δ = 8.33 (s, 1 H), 7.54 (d, J = 9.0 Hz, 1 H), 7.36 (t, J = 7.2 Hz, 1 H), 7.31 (d, 
J = 9 Hz, 1 H), 7.16 (br s, 1 H), 7.12 (d, J = 7.5 Hz, 1 H), 6.97 (br d, J = 7.2 Hz, 1 H), 
5.73 (s, 1 H), 4.40 (br s, 1 H), 4.19 (dd, J = 8.7 Hz, 4.5 Hz, 1 H), 4.05 (m, 1 H), 3.85 
(s, 3 H), 3.83-3.65 (m, 2 H); 13C NMR (75 MHz, CD3OD): δ = 179.1, 161.4, 156.1, 
150.5, 145.9, 144.5, 135.2, 130.7, 125.6, 122.8, 121.7, 116.4, 116.2, 115.0, 113.8, 
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109.1, 88.5, 83.0, 78.9, 63.3, 56.1; ESI-MS (m/z): 417.2 (M + H+), 439.2 (M + Na+), 
455.2 (M + K+); HRMS (MALDI) calcd for C21H21O9+ 417.1180, Found: 417.1188. 
8-Hydroxy-4’-methylisoflavon-7-yl α-D-arabinofuranoside (22e): Rf  0.27 (CHCl3 : 
MeOH = 10 : 1); [α]D24 = 37.1 (c 0.17, MeOH); 1H NMR (300 MHz, CD3OD): δ = 
8.18 (s, 1 H), 7.54 (d, J = 9.0 Hz, 1 H), 7.34 (d, J = 7.5 Hz, 2 H), 7.24 (d, J = 9.0 Hz, 
1 H), 7.15 (d, J = 7.5 Hz, 2 H), 5.66 (s, 1 H), 4.30 (br s, 1 H), 4.08 (dd, J = 8.7 Hz, 4.5 
Hz, 1 H), 3.98 (br s, 1 H), 3.66 (dd, J = 11.7 Hz, 3.9 Hz, 1 H), 3.62 (dd, J = 11.7 Hz, 
4.8 Hz, 1 H), 2.28 (s, 3 H); ESI-MS (m/z): 401.0 (M + H+), 423.0 (M + Na+); HRMS 
(MALDI) calcd for C21H21O8+ 401.1231, Found: 401.1235. 
8-Hydroxy-2’-methylisoflavon-7-yl α-D-arabinofuranoside (22f): Rf  0.39 (CHCl3 : 
MeOH = 10 : 1); [α]D24 = 52.1 (c 0.10, MeOH); 1H NMR (300 MHz, CD3OD): δ = 
8.13 (s, 1 H), 7.40 (d, J = 8.7 Hz, 1 H), 7.34-7.16 (m, 5 H), 5.71 (s, 1 H), 4.39 (br s, 1 
H), 4.20 (dd, J = 8.7 Hz, 4.5 Hz, 1 H), 4.03 (m, 1 H), 3.76 (dd, J = 11.7 Hz, 3.9 Hz, 1 
H), 3.67 (dd, J = 11.7 Hz, 5.1 Hz, 1 H), 2.21 (s, 3 H) ; ESI-MS (m/z): 401.2 (M + H+), 
423.2 (M + Na+), 439.0 (M + K+); HRMS (MALDI) calcd for C21H20O8Na+ 423.1050, 
Found: 423.1058. 
8-Hydroxy-3’-methylisoflavon-7-yl α-D-arabinofuranoside (22g): Rf  0.35 (CHCl3 : 
MeOH = 10 : 1); [α]D24 = 17.7 (c 0.13, MeOH); 1H NMR (300 MHz, CD3O D): δ = 
8.32 (s, 1 H), 7.78-7.63 (m, 2 H), 7.42-7.29 (m, 3 H), 7.22 (br s, 1 H), 5.79 (s, 1 H), 
4.43 (br s, 1 H), 4.21 (dd, J = 8.7 Hz, 4.5 Hz, 1 H), 4.10 (m, 1 H), 3.78 (dd, J = 11.7 
Hz, 3.9 Hz, 1 H), 3.71 (dd, J = 11.7 Hz, 5.1 Hz, 1 H), 2.41 (s, 3 H); ESI-MS (m/z): 
401.2 (M + H+), 423.2 (M + Na+), 439.2 (M + K+); HRMS (ESI) calcd for 
C21H20O8Na+ 423.1050, Found: 423.1051. 
4’,8-Dihydroxyisoflavon-7-yl α-D-arabinofuranoside (22h, A-76202)[10] 
3’,8-Dihydroxyisoflavon-7-yl α-D-arabinofuranoside (22i): Rf  0.23 (CHCl3 : 
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MeOH = 8 : 1); [α]D24 = 99.7 (c 0.08, MeOH); 1H NMR (300 MHz, CD3OD): δ = 8.31 
(s, 1 H), 7.67 (d, J = 8.7 Hz, 1 H), 7.37 (d, J = 8.7 Hz, 1 H), 7.28 (t, J = 7.5 Hz, 1 H), 
7.05 (br s, 1 H), 7.03 (d, J = 8.1 Hz, 1 H), 6.85 (br d, J = 6.6 Hz, 1 H), 5.79 (s, 1 H), 
4.43 (br s, 1 H), 4.22 (dd, J = 8.7 Hz, 4.5 Hz, 1 H), 4.11 (m, 1 H), 3.79 (dd, J = 11.7 
Hz, 3.9 Hz, 1 H), 3.74 (dd, J = 11.7 Hz, 5.1 Hz, 1 H); 13C NMR (75 MHz, CD3OD): δ 
= 178.6, 158.8, 155.7, 150.0, 148.7, 138.9, 134.9, 130.7, 126.2, 121.7, 117.7, 116.5, 
116.4, 116.2, 109.4, 88.9, 83.0, 79.0, 63.4; ESI-MS (m/z): 403.0 (M + H+), 425.0 (M 
+ Na+); HRMS (MALDI) calcd for C20H19O9+ 403.1024, Found: 403.1028. 
4’-Fluoro-8–hydroxyisoflavon-7-yl α-D-arabinofuranoside (22j): Rf  0.42 (CHCl3 : 
MeOH = 8 : 1); [α]D24 = 31.6 (c 0.16, MeOH); 1H NMR (300 MHz, CD3OD): δ = 8.34 
(s, 1 H), 7.65-7.56 (m, 3 H), 7.34 (d, J = 9.0 Hz, 1 H), 7.19 (t, J = 8.4 Hz, 2 H), 5.77 
(s, 1 H), 4.41 (br s, 1 H), 4.21 (dd, J = 8.7 Hz, 4.5 Hz, 1 H), 4.09 (m, 1 H), 3.78 (dd, J 
= 11.7 Hz, 3.9 Hz, 1 H), 3.73 (dd, J = 11.7 Hz, 5.1 Hz, 1 H); ESI-MS (m/z): 405.2 (M 
+ H+), 427.2 (M + Na+); HRMS (ESI) calcd for C20H17O8FNa+ 427.0800, Found: 
427.0795. 
4’-(Dimethylamino)-8-hydroxyisoflavon-7-yl α-D-arabinofuranoside (22k): Rf  
0.30 (CHCl3 : MeOH = 10 : 1); [α]D24 = 104.6 (c 0.10, MeOH); 1H NMR (300 MHz, 
CD3OD): δ = 8.22 (s, 1 H), 7.43 (d, J = 8.4 Hz, 3 H), 7.25 (d, J = 9.0 Hz, 1 H), 6.84 (d, 
J = 8.4 Hz, 2 H), 5.69 (s, 1 H), 4.40 (br s, 1 H), 4.20 (dd, J = 8.7 Hz, 4.5 Hz, 1 H), 
4.02 (m, 1 H), 3.77 (dd, J = 11.7 Hz, 3.0 Hz, 1 H), 3.71 (dd, J = 11.7 Hz, 5.1 Hz, 1 H), 
2.96 (br s, 6 H); 13C NMR (75 MHz, CD3OD): δ = 180.0, 155.0, 152.3, 150.6, 144.4, 
131.1, 125.6, 122.1, 116.7, 124.0, 112.1, 109.1, 88.3, 83.0, 79.0, 63.4, 41.1; ESI-MS 
(m/z): 430.0 (M + H+); HRMS (ESI) calcd for C22H23O8NNa+ 452.1316, Found: 
452.1320. 
4’-(tert-Butoxycarbonylamino)-8–hydroxyisoflavon-7-yl α-D-arabinofuranoside 
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(22l): Rf  0.42 (CHCl3 : MeOH = 10 : 1); [α]D24 = 45.6 (c 0.10, MeOH); 1H NMR 
(300 MHz, CD3OD): δ = 8.57 (s, 1 H), 8.28 (s, 1 H), 7.60 (d, J = 9.0 Hz, 1 H), 7.48 
(br s, 4 H), 7.31 (d, J = 9.0 Hz, 1 H), 5.75 (s, 1 H), 4.40 (br s, 1 H), 4.17 (dd, J = 8.7 
Hz, 4.5 Hz, 1 H), 4.07 (m, 1 H), 3.79 (dd, J = 11.7 Hz, 3.9 Hz, 1 H), 3.71 (dd, J = 11.7 
Hz, 5.1 Hz, 1 H), 1.53 (s, 9H); ESI-MS (m/z): 502.0 (M + H+), 524.0 (M + Na+); 
HRMS (MALDI) calcd for C25H27O10NNa+ 524.1527, Found: 524.1532. 
8-Hydroxy-4’-(trifluoromethyl)isoflavon-7-yl α-D-arabinofuranoside (22m): Rf 
0.43 (CHCl3 : MeOH = 10 : 1); [α]D24 = 37.5 (c 0.23, MeOH); 1H NMR (300 MHz, 
CDCl3): δ = 8.41 (s, 1 H), 7.83-7.65 (m, 4 H), 7.57 (d, J = 8.4 Hz, 1 H), 7.32 (d, J = 
7.8 Hz, 1 H), 5.77 (s, 1 H), 4.42 (br s, 1 H), 4.21 (dd, J = 7.8 Hz, 4.5 Hz, 1 H), 4.09 
(m, 1 H), 3.82-3.74 (m, 2 H); 13C NMR (75 MHz, CD3OD): δ = 178.3, 156.4, 150.3, 
149.1, 140.6, 138.1, 131.1, 126.4, 124.6, 121.7, 116.4, 115.1, 109.3, 88.9, 82.8, 79.0, 
63.4, 31.0; ESI-MS (m/z): 455.0 (M + H+), 477.0 (M + Na+); HRMS (ESI) calcd for 
C21H17O8F3Na+ 477.0768, Found: 477.0768. 
8-Hydroxy-4’-(trimethylsilyl)isoflavon-7-yl α-D-arabinofuranoside (22n): Rf  0.58 
(CH2Cl2 : MeOH = 8 : 1); [α]D24 = 49.1 (c 0.12, MeOH); 1H NMR (300 MHz, 
CD3OD): δ = 8.32 (s, 1 H), 7.71-7.46 (m, 5 H), 7.32 (d, J = 8.7 Hz, 1 H), 5.76 (s, 1 H), 
4.42 (br s, 1 H), 4.21 (dd, J = 8.7 Hz, 4.5 Hz, 1 H,), 4.07 (br s, 1 H), 3.86-3.64 (m, 2 
H), 0.30 (s, 9 H); ESI-MS (m/z): 459.0 (M + H+). 
5-Hydroxyisoflavon-7-yl α-D-arabinofuranoside (23a): Rf  0.42 (CH2Cl2 : MeOH = 
10 : 1); [α]D24 = 86.7 (c 0.15, MeOH); 1H NMR (300 MHz, CD3OD): δ = 8.20 (s, 1 H), 
7.56 (d, J = 6.6 Hz, 2 H), 7.48-7.34 (m, 3 H), 6.70 (br s, 1 H), 6.50 (br s, 1 H), 5.65 (s, 
1 H), 4.29 (br s, 1 H), 4.13-3.96 (m, 2 H), 3.78 (dd, J = 12.0 Hz, 2.4 Hz, 1 H), 3.69 
(dd, J = 12.0 Hz, 4.5 Hz, 1 H); ESI-MS (m/z): 387.0 (M + H+), 409.0 (M + Na+); 
HRMS (ESI) calcd for C20H19O8+ 387.1074, Found: 387.1075. 
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5-Hydroxy-4’-methoxyisoflavon-7-yl α-D-arabinofuranoside (23b): Rf 0.48 
(CH2Cl2 : MeOH = 10 : 1); [α]D24 = 68.6 (c 0.19, MeOH); 1H NMR (300 MHz, 
CD3OD): δ = 8.17 (s, 1 H), 7.50 (d, J = 7.2 Hz, 2 H), 6.99 (d, J = 7.2 Hz, 2 H), 6.69 
(br s, 1 H), 6.50 (br s, 1 H), 5.67 (s, 1 H), 4.31 (br s, 1 H), 4.13-4.02 (m, 2 H), 3.84 (s, 
3 H), 3.80 (dd, J = 12.0 Hz, 3.0 Hz, 1 H), 3.73 (dd, J = 12.0, 4.5 Hz, 1 H); ESI-MS 
(m/z): 417.0 (M + H+), 439.0 (M + Na+); HRMS (MALDI) calcd for C21H21O9+ 
417.1180, Found: 417.1186. 
5-Hydroxy-2’-methoxyisoflavon-7-yl α-D-arabinofuranoside (23c): Rf 0.49 
(CH2Cl2 : MeOH = 10 : 1); [α]D24 = 74.6 (c 0.19, MeOH); 1H NMR (300 MHz, 
CD3OD): δ = 8.28 (s, 1 H), 7.63 (t, J = 8.4 Hz, 1 H), 7.50 (d, J = 7.2 Hz, 1 H), 7.30 (d, 
J = 8.4 Hz, 1 H), 7.24 (t, J = 7.2 Hz, 1 H), 6.93 (d, J = 1.8 Hz, 1 H), 6.74 (d, J = 1.8 
Hz, 1 H), 5.89 (s, 1 H), 4.53 (d, J = 2.1 Hz, 1 H), 4.35-4.22 (m, 2 H), 4.04 (dd, J = 
12.0 Hz, 3.0 Hz, 1 H), 4.03 (s, 3 H), 3.93 (dd, J = 12.0 Hz, 4.5 Hz, 1 H); ESI-MS 
(m/z): 417.2 (M + H+); HRMS (ESI) calcd for C21H21O9+ 417.1180, Found: 417.1190. 
5-Hydroxy-3’-methoxyisoflavon-7-yl α-D-arabinofuranoside (23d): Rf 0.47 
(CH2Cl2 : MeOH = 10 : 1); [α]D24 = 89.2 (c 0.08, MeOH); 1H NMR (300 MHz, 
CD3OD): δ = 8.22 (br s, 1 H), 7.34 (t, J = 7.5 Hz, 1 H), 7.15 (br s, 1 H), 7.11 (d, J = 
7.5 Hz, 1 H), 6.96 (d, J = 7.5 Hz, 1 H), 6.70 (d, J = 1.5 Hz, 1 H), 6.51 (d, J = 1.5 Hz, 1 
H), 5.65 (br s, 1 H), 4.29 (d, J = 3.6 Hz, 1 H), 4.10-3.98 (m, 2 H), 3.82 (s, 3 H), 3.78 
(dd, J = 12.0, 3.0 Hz, 1 H), 3.70 (dd, J = 12.0 Hz, 4.5 Hz); ESI-MS (m/z): 417.2 (M + 
H+), 439.2 (M + Na+); HRMS (ESI) calcd for C21H21O9+ 417.1180, Found: 417.1178. 
5-Hydroxy-4’-methylisoflavon-7-yl α-D-arabinofuranoside (23e): Rf 0.50 (CH2Cl2 : 
MeOH = 10 : 1); [α]D24 = 136.7 (c 0.13, MeOH); 1H NMR (300 MHz, CD3OD): δ = 
8.16 (s, 1 H), 7.43 (d, J = 7.8 Hz, 2 H), 7.24 (d, J = 7.8 Hz, 2 H), 6.68 (br s, 1 H), 6.49 
(br s, 1 H), 5.64 (s, 1 H), 4.29 (br s, 1 H), 4.13-3.98 (m, 2 H), 4.06 (dd, J = 12.0 Hz, 
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3.0 Hz, 1 H), 3.98 (dd, J = 12.0 Hz, 4.5 Hz, 1 H), 2.37 (s, 3 H); ESI-MS (m/z): 401.1 
(M + H+), 423.1 (M + Na+); HRMS (ESI) calcd for C21H21O8+ 401.1231, Found: 
401.1232. 
5-Hydroxy-3’-methylisoflavon-7-yl α-D-arabinofuranoside (23f): Rf 0.49 (CH2Cl2 : 
MeOH = 10 : 1); [α]D24 = 97.6 (c 0.10, MeOH); 1H NMR (300 MHz, CD3OD): δ = 
8.16 (s, 1 H), 7.40-7.30 (m, 3 H), 7.22 -7.18(d, J = 7.2 Hz, 1 H), 6.69 (br s, 1 H), 6.51 
(br s, 1 H), 5.64 (br s, 1 H), 4.28 (br s, 1 H), 4.12-3.98 (m, 2 H), 3.84-3.63 (m, 2 H), 
2.39 (s, 3 H); ESI-MS (m/z): 401.1 (M + H+), 423.0 (M + Na+); HRMS (ESI) calcd 
for C21H20O8Na+ 423.1050, Found: 423.1050. 
4’,5-Dihydroxyisoflavon-7-yl α-D-arabinofuranoside (23g): Rf 0.28 (CH2Cl2 : 
MeOH = 10 : 1); [α]D24 = 37.1 (c 0.15, MeOH); 1H NMR (300 MHz, CD3OD): δ = 
8.15 (s, 1 H), 7.39 (d, J = 8.4 Hz, 2 H), 6.85 (d, J = 8.4 Hz, 2 H), 6.69 (d, J = 1.5 Hz, 
1 H), 6.50 (d, J = 1.5 Hz, 1 H), 5.65 (br s, 1 H), 4.29 (d, J = 3.6 Hz, 1 H), 4.07 (m, 1 
H), 4.02 (dd, J = 6.6 Hz, 3.9 Hz, 1 H), 3.78 (dd, J = 12.0, 2.7 Hz, 1 H), 3.70 (dd, J = 
12.0, 4.5 Hz, 1 H); ESI-MS (m/z): 403.1 (M + H+), 425.2 (M + Na+); HRMS (ESI) 
calcd for C20H19O9+ 403.1024, Found: 403.1025. 
3’,5-Dihydroxyisoflavon-7-yl α-D-arabinofuranoside (23h): Rf 0.29 (CH2Cl2 : 
MeOH = 10 : 1); [α]D24 = 49.2 (c 0.17, MeOH); 1H NMR (300 MHz, CD3OD): δ = 
8.18 (s, 1 H), 7.24 (t, J = 7.8 Hz, 1 H), 7.02 (br s, 1 H), 7.00 (d, J = 7.8 Hz, 1 H), 6.82 
(d, J = 7.8 Hz, 1 H), 6.69 (br s, 1 H), 6.50 (br s, 1 H), 5.65 (s, 1 H), 4.29 (d, J = 3.0 Hz, 
1 H), 4.07 (m, 1 H), 4.03 (dd, J = 6.6 Hz, 3.9 Hz, 1 H), 3.79 (dd, J = 12.0, 2.7 Hz, 1 
H), 3.69 (dd, J = 12.0, 4.8 Hz, 1 H); ESI-MS (m/z): 403.1 (M + H+); HRMS (MALDI) 
calcd for C20H19O9+ 403.1024, Found: 403.1030. 
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